BPC-157 test results: how often vials pass lab testing
Nearly half of recent BPC-157 samples failed lab testing. Here are the numbers, what HHS's October 2026 draft policy changes, and what it does not change for a research-labelled vial.
Of the last 196 BPC-157 samples with a result in Finnrick's public lab-testing database, 106 passed and 90 failed: 54 percent of BPC-157 test results were a pass. Another 4 came back incomplete and are left out. Finnrick has published 950 BPC-157 tests from 149 sellers since 17 Dec 2024.
BPC-157 is a synthetic 15-amino-acid peptide, a partial sequence of a protein found in human gastric juice. Its evidence rests almost entirely on animal studies. It is also one of the most bought research peptides, and the test data says close to half of what is sold fails a basic quality check.
The short version
- 54 percent of recent samples passed. 106 passed and 90 failed, of the last 196 with a result.
- It is not FDA-approved. HHS published a draft policy in October 2026 that would let licensed pharmacies compound it on a prescription under strict conditions. It is a draft.
- A pass is a narrow result. It covers identity, purity and fill for the vial that was tested. It does not cover endotoxin, sterility or the next batch.
- We do not name sellers. The numbers describe the market, not any one shop.
BPC-157 test results in numbers
| Measure | BPC-157 |
|---|---|
| Published tests | 950 |
| Sellers with at least one test | 149 |
| First and latest test | 17 Dec 2024 to 6 Nov 2026 |
| Recent results counted | 196 (4 incomplete left out) |
| Passed | 106 |
| Failed | 90 |
| Pass rate | 54% |
| Rank by pass rate | 8 of 14 on our peptide test results page |
Figures from Finnrick's public BPC-157 page, checked on 12 November 2026. They will change as new results come in.
What counts as a pass or a fail
These figures use Finnrick's "Purity focus" standard, the one its public pages show. A sample passes when its purity is at least 99.5 percent and the amount in the vial is within 35 percent of the label. A sample that turns out to be a different molecule fails under every standard Finnrick uses. Endotoxin testing is not required under this standard, so a pass says nothing about endotoxin or sterility.
The pass rate counts passes and fails among the most recent results on Finnrick's public page, up to 200, and leaves out tests that came back incomplete. Finnrick says it sources samples from sellers and sends them to third-party labs, with HPLC as the main method. Its methodology page has the detail.
Is BPC-157 FDA-approved?
No. BPC-157 is not approved for human use (see our BPC-157 page). FDA took it out of Category 2 in April 2026, and on 23 July 2026 FDA's compounding advisory committee recommended it for the 503A bulks list (what that vote means). On 30 October 2026 HHS published a draft enforcement discretion policy covering BPC-157 and five other peptides. Under it, a state-licensed pharmacy could compound BPC-157 on a patient-specific prescription, from a registered manufacturer with a valid certificate of analysis, with set labelling. It is a draft, comments close on 13 November 2026, and it does not cover research-use-only products.
Nearly half of recent BPC-157 samples failed
Of the last 196 BPC-157 samples with a result, 90 failed and 106 passed. Finnrick has published 950 BPC-157 tests from 149 sellers since 17 Dec 2024.
The HHS draft is interesting for exactly this reason. Its conditions ask for a certificate of analysis and a registered, inspected source, which is the paperwork a research-labelled vial does not come with. If the draft is finalised, a pharmacy route would exist. Today it is a proposal.
Before you buy BPC-157
There is no approved BPC-157 product, and the pharmacy route in the HHS draft does not exist until the policy is final. Peptide AI will only offer a prescription route for what can legally be prescribed.
Before any order, three checks come first: the steps in how to vet a peptide supplier, an independent result for your own lot (how to get peptides tested), and the legal picture in is it legal to buy peptides. Products sold as research use only are not FDA-approved drugs, and a passing test does not make one safe to use.
Peptide AI is building a marketplace with two ways to buy: on a prescription through licensed telehealth, for what can legally be prescribed, or from vetted suppliers with an independent lab report you read before you order. It is not open yet. Early access is here.
Questions people ask
What percentage of BPC-157 fails lab testing?
In Finnrick's public test database, 90 of the last 196 BPC-157 samples with a result failed, which is 46 percent, and 106 passed. Tests that came back incomplete are left out.
Is BPC-157 FDA-approved?
It is not FDA-approved. HHS published a draft policy in October 2026 that would let licensed pharmacies compound it on a prescription under strict conditions. It is a draft.
Does a passing lab test mean BPC-157 is safe?
No. A pass means the sample matched its label on identity, purity and fill under one standard. It does not cover endotoxin, sterility, other vials, or whether BPC-157 is safe or does anything in people.
Does the HHS draft make research BPC-157 legal?
No. The draft covers compounding by licensed pharmacies on a prescription, from a registered source with a valid certificate of analysis. It does not cover research-use-only products, and it is still a draft.
Sources
- Methodology, Finnrick, accessed 12 November 2026
- BPC-157 product page and public test history, Finnrick, accessed 12 November 2026
- HHS announces interim enforcement discretion for section 503A compounding with certain peptide bulk drug substances, Venable LLP, 6 November 2026
